Maravai LifeSciences (MRVI) Tops Q1 EPS by 4c
Get Alerts MRVI Hot Sheet
Join SI Premium – FREE
Maravai LifeSciences (NASDAQ: MRVI) reported Q1 EPS of $0.24, $0.04 better than the analyst estimate of $0.20. Revenue for the quarter came in at $148.2 million versus the consensus estimate of $138.49 million.
GUIDANCE:
Maravai LifeSciences sees FY2021 EPS of $1.04-$1.12, versus the consensus of $0.89. Maravai LifeSciences sees FY2021 revenue of $680-720 million, versus the consensus of $610.97 million.
For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Walgreens Boots Alliance (WBA) tops Q2 expectations, narrows full-year profit forecast
- Can-Fite BioPharma (CANF) Reports FY23 Results, Issues Clinical Update
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!